Cota Inc, New York, has been granted a US patent for the development of its Cota Nodal Address (CNA) system, a digital patient classification system that transforms prognostically significant attributes into a digital code.
The CNA was developed to categorize patient factors, type and stage of cancer, and intended therapies, in order to measure treatment outcomes precisely. The system also enables the identification of variants in care, provides benchmarking, and highlights clear paths for research and discovery.
“Cota’s CNA classification system is a transformative approach to applying Big Data to healthcare,” says Andrew Pecora, MD, inventor of the technology, founder and executive chairman of Cota, and chief innovations officer of Hackensack University Medical Center. “Due to the skyrocketing cost of cancer care, we began our work on the CNA system with a dedicated group of cancer specialists at the John Theurer Cancer Center at Hackensack. We were able to fully develop and test the use of Cota’s CNA classification system in actual clinical practice, where we were able to show increased clinical and economic value.”
“The CNA is going to revolutionize how care is provided, paid for, and researched,” says Eric Schultz, CEO of Cota. “Each critical member involved in healthcare, including the patient, provider, payor, and pharmaceutical industry, will benefit from the clear insights Cota’s patented CNA classification system will provide. This is a transformative tool that will result in reducing patient suffering and extending lives while reducing wasteful spending.”
According to the American Institute of Cancer Research, cancer costs $895 billion annually—far more than any other disease—and the pool of resources to pay for those costs are being reduced. Additionally, with an estimated 30% of every dollar spent in healthcare being wasted, the stakes for payors and the healthcare system are high.
Cota’s CNA classification system provides a clear path for providers to reduce treatment variance, and thus helps identify, reduce, or eliminate wasteful spending. Cota’s CNA architecture is supported by the firm’s proprietary technology, which includes the Influx platform. Through Influx, Cota acquires, processes, and structures all incoming data by extracting key facts from unstructured data. Influx unlocks patient data and enables oncologists to make important diagnostic and care decisions in real time.
Additionally, the CNA system also reduces the processing requirements and time needed to make real-time monitoring of medical providers’ performance more efficient. With precise predictions of when behavioral variance is likely to occur, the CNA assists physicians in accurately interrupting treatment flow to avoid both over- and underutilization of care.
Cota’s CNA classification system has been developed for all types and stages of cancer, and will soon be expanding to increase the value of care for all medical conditions.
For more information, visit Cota.